Phenotypes Associated with This Genotype

Genotype
MGI:2174783

• Allelic Composition: Trp53^tm1Tyj/Trp53⁺
• Genetic Background: involves: 129S2/SvPas * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:95318 )

• heterozygous mutants die between 150 to 750 days after birth

decreased tumor-free survival time ( J:17728 , J:135509 )

• 28% of mutants die by 17 months of age due to tumors (J:17728)

• less than 5% of mice live past two years due to cancerous tumors (J:135509)

neoplasm

abnormal tumor morphology ( J:17728 )

• tumors show loss of heterozygosity for Trp53

increased tumor incidence ( J:17728 , J:135509 )

• age of onset 9 months (J:17728)

• over 95% of mice have tumors by 2 years of age (J:135509)

increased pancreas tumor incidence ( J:72391 )

• 2.9% incidence of pancreatic adenocarcinomas

increased adenoma incidence ( J:72391 )

• 5.9% incidence

increased leukemia incidence ( J:135509 )

• is observed in 2.6% of mice by 24 months of age

increased lymphoma incidence ( J:17728 , J:72391 )

• 25% of mutants exhibit lymphomas (J:17728)

• 32% incidence (J:72391)

increased histiocytic sarcoma incidence ( J:72391 )

• 15% incidence

increased carcinoma incidence ( J:72391 , J:95318 )

• 35% incidence of carcinomas (J:72391)

• 2.9% incidence of pancreatic adenocarcinomas (J:72391)

• 12% of heterozygous mutants developed carcinomas, which are rare in homozygotes (J:95318)

increased adenocarcinoma incidence ( J:72391 )

• 18% incidence

increased mammary adenocarcinoma incidence ( J:72391 )

• 2.9% incidence

increased lung adenocarcinoma incidence ( J:72391 )

• 12% incidence

increased squamous cell carcinoma incidence ( J:72391 )

• 18% incidence of ear squamous cell carcinoma

increased sarcoma incidence ( J:17728 , J:72391 , J:95318 )

• 57% of mutants exhibit sarcomas (J:17728)

• 56% incidence of sarcomas (J:72391)

• 2.9% incidence of undifferentiated sarcomas (J:72391)

• 56% of heterozygous mutants developed sarcomas (J:95318)

increased leiomyosarcoma incidence ( J:17728 )

increased rhabdomyosarcoma incidence ( J:17728 )

increased fibrosarcoma incidence ( J:17728 )

increased hemangiosarcoma incidence ( J:17728 , J:72391 )

• 8.8% incidence (J:72391)

increased osteosarcoma incidence ( J:17728 , J:72391 )

• 29% incidence (J:72391)

endocrine/exocrine glands

increased mammary adenocarcinoma incidence ( J:72391 )

• 2.9% incidence

increased pancreas tumor incidence ( J:72391 )

• 2.9% incidence of pancreatic adenocarcinomas

integument

increased mammary adenocarcinoma incidence ( J:72391 )

• 2.9% incidence

digestive/alimentary system

intestine polyps ( J:72391 )

• 2.9% incidence of small intestinal polyps

gastric polyps ( J:72391 )

• 2.9% incidence of stomach polyps

muscle

increased leiomyosarcoma incidence ( J:17728 )

increased rhabdomyosarcoma incidence ( J:17728 )

respiratory system

increased lung adenocarcinoma incidence ( J:72391 )

• 12% incidence

skeleton

increased osteosarcoma incidence ( J:17728 , J:72391 )

• 29% incidence (J:72391)

homeostasis/metabolism

abnormal iron level ( J:244082 )

• Pearl's Prussian blue staining revealed mild iron overload in E8.0 embryos

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Li-Fraumeni syndrome		DOID:3012	OMIM:PS151623	J:17728